Updates

Date: August 04, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department PhirozeJeejeebhoi Towers, Exchange Plaza, C-1, Block-G, Dalal Street, Bandra-Kurla Complex, Mumbai - 400001. Bandra (East), Mumbai - 400051. Scrip Code: 524404 Symbol: MARKSANS Sub: Submission of Business Responsibility and Sustainability Report for financial year 2025-26 Dear Sir/Madam, Pursuant to provisions of Regulation 34 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable regulations, kindly find enclosed herewith the Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. We request you to take the aforesaid on records. Thanking You. For Marksans Pharma Limited Harshavardhan Panigrahi Company Secretary Encl.: As Above Marksans Pharma Ltd. 11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: companysecretary@marksanspharma.com www.marksanspharma.com Corporate Overview Statutory Reports Financial Statements Annexure - F Annexure to the Report of the Board of directors BUSINESS RESPONSIBILITY & SUSTAINABILITY REPORT 2025-26 SECTION A: GENERAL DISCLOSURES I. Details of the listed entity Particulars Details 1. Corporate Identity Number (CIN) of the Listed Entity L24110MH1992PLC066364 2. Name of the Listed Entity MARKSANS PHARMA LIMITED 3. Year of incorporation 1992 4. Registered Office address 11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai- 400053 5. Corporate address 11th Floor, Grandeur, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai- 400053 6. E-mail id companysecretary@marksanspharma.com 7. Telephone (022) 4001 2000 8. Website www.marksanspharma.com 9. Financial Year for which reporting is being done April 01, 2025 to March 31, 2026 10. Name of the Stock Exchange(s) where shares are listed National Stock Exchange of India Limited BSE Limited 11. Paid-up Capital Rs. 45,31,63,746 12. Name and contact details (telephone, email address) of the Name: Harshavardhan Panigrahi person who may be contacted in case of any queries on the Designation: Company Secretary BRSR report Phone No.: (022) 4001 2000 E-mail ID: companysecretary@marksanspharma.com 13. Reporting boundary - Are the disclosures under this report Standalone made on a standalone basis (i.e. only for the entity) or on a consolidated basis (i.e. for the entity and all the entities which form a part of its consolidated financial statements taken together). 14. Name of assurance provider - 15. Type of assurance obtained - II. Products/services 16. Details of business activities (accounting for 90% of the turnover): Description of Main Activity Description of Business Activity % of Turnover of the entity 1. Pharmaceutical Formulation Research, manufacturing and sales of generics, speciality, 100 OTC and Rx pharmaceutical products in pain management, upper respiratory, CVS, CNS, gastrointestinal, anti- diabetic, anti-infective, anti-allergic, oncology, etc. 17. Products/Services sold by the entity (accounting for 90% of the entity’s Turnover): Product/Service NIC Code % of total Turnover contributed 1. Solid Orals, Tablets, Capsules (including Soft Gelatin 2100 100 Capsules), Ointments, Liquids and Creams. Marksans Pharma Limited 81 III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated: Location Number of plants Number of offices Total National 2 2 4 International 2 4 6 19. Markets served by the entity: a) Number of locations Locations Number National (No. of States) - International (No. of Countries) 50+ b) What is the contribution of exports as a percentage of the total turnover of the entity? 100% c) A brief on types of customers The Company serves a broad customer base across key therapeutic areas. These products address the needs of a wide range of patients, through a comprehensive distribution network that includes wholesalers, distributors, retail chains, pharmacy stores, hospitals and government institutions. Furthermore, the Company extends its global presence by exporting products to international markets through both its subsidiaries and third-party distributors. IV. Employees 20. Details at the end of Financial Year: a) Employees and workers (including differently abled): Sr. Male Female Particulars Total (A) No No. (B) % (B / A) No. (C) % (C / A) Employees 1. Permanent (D) 1159 999 86.20 160 13.80 2. Other than Permanent (E) 72 53 73.61 19 26.39 3. Total employees (D + E) 1231 1052 85.46 179 14.54 Workers 4. Permanent (F) 526 526 100 0 0 5. Other than Permanent (G) 478 360 75.31 118 24.69 6. Total workers (F + G) 1004 886 88.25 118 11.75 b) Differently abled Employees and workers: Sr. Male Female Particulars Total (A) No No. (B) % (B / A) No. (C) % (C / A) DIFFERENTLY ABLED EMPLOYEES 1. Permanent (D) 0 0 0 0 0 2. Other than Permanent (E) 0 0 0 0 0 3. Total differently abled 0 0 0 0 0 employees (D + E) DIFFERENTLY ABLED WORKERS 4. Permanent (F) 0 0 0 0 0 5. Other than Permanent (G) 0 0 0 0 0 6. Total differently abled 0 0 0 0 0 workers (F + G) 82 Annual Report 2025-26 Corporate Overview Statutory Reports Financial Statements 21. Participation/Inclusion/Representation of women: No. and percentage of Females Total (A) No. (B) % (B / A) Board of Directors 8 2 25% Key Management Personnel 2 0 0 22. Turnover rate for permanent employees and workers (for the past 3 years): FY (2025-26) FY (2024-25) FY (2023-24) (Turnover rate in the (Turnover rate in current FY) (Turnover rate in previous FY) year prior to the previous FY) Male Female Total Male Female Total Male Female Total Permanent Employees 25.17 6.38 22.29 14.77 17.99 15.32 15 3 18 Permanent Workers 12.31 0 11.40 12.57 0 12.57 12 0 12 V. Holding, Subsidiary and Associate Companies (including joint ventures) 23. Names of holding / subsidiary / associate companies / joint ventures: Does the entity indicated Indicate whether % of shares at column A, participate in Sr. Name of the holding / subsidiary / holding/ Subsidiary/ held by listed the Business Responsibility No associate companies / joint ventures (A) Associate/ Joint Venture entity initiatives of the listed entity? (Yes/No) 1. Marksans Pharma (UK) Limited Subsidiary 100 No 2. Marksans Holdings Limited Step down Subsidiary 100 No 3. Bell, Sons & Co. (Druggists) Limited Step down Subsidiary 100 No 4. Relonchem Limited Step down Subsidiary 100 No 5. Marksans Pharma Inc. Subsidiary 100 No 6. Time-Cap Laboratories Inc. Step down Subsidiary 100 No 7. Custom Coatings Inc. Step down Subsidiary 100 No 8. Marksans Realty LLC Step down Subsidiary 100 No 9. Marise Ann Inc. Step down Subsidiary 100 No 10. Nova Pharmaceuticals Australasia Pty. Ltd. Subsidiary 60 No 11. Nova Pharmaceuticals NZ Limited Step down Subsidiary 100 No 12. Access Healthcare for Medical Products LLC Subsidiary 100 No 13. Marksans Pharma GmbH Subsidiary 100 No 14. Marksans Pharma (Europe) Limited Subsidiary 100 No 15. Marksans (Canada) Inc. Subsidiary 100 No VI. CSR Details 24. i. Whether CSR is applicable as per section 135 of Companies Act, 2013: Yes ii. Turnover (in Rs.): 1341.47 crores iii. Net worth (in Rs.): 1,652.31 crores Marksans Pharma Limited 83 VII. Transparency and Disclosures Compliances 25. Complaints/Grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct: FY2025-26 FY2024-25 Stakeholder Number of Number of Grievance Redressal Mechanism Number of Number of group from complaints complaints in Place (Yes/No) (If Yes, then complaints complaints whom pending pending provide web-link for grievance filed Remarks filed Remarks complaint is resolution at resolution at redressal policy) during the during the received close of the close of the year year year year Communities The Company reaches out to Nil NA - Nil NA [Showing first 8,000 characters — download PDF for full document]